Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai 201508, China.
J Immunol Res. 2022 Jul 26;2022:3621496. doi: 10.1155/2022/3621496. eCollection 2022.
Recent studies show that myeloid-derived suppressor cells (MDSCs) and M2-like macrophages are involved in the treatment of tumors; however, their therapeutic response role is rarely known in non-small cell lung cancer (NSCLC) during radiotherapy. We aim to explore the dynamic alteration of the circulating MDSCs and M2-like macrophages, to examine their relationship, and to evaluate their therapeutic response value for NSCLC patients in radiotherapy.
Peripheral blood mononuclear cells from healthy controls and NSCLC patients with different radiotherapy phases were isolated to examine the circulating MDSCs and M2-like macrophages by flow cytometry. 40 plasma inflammatory cytokines were measured by multiplex ELISA.
In comparison with healthy controls, the percentages of MDSCs and CD68CD163M2-like macrophages of NSCLC patients were significantly elevated and were distinctly higher in radiotherapy than in preradiotherapy. MDSCs were correlated positively with CD68CD163M2-like macrophages in NSCLC patients in radiotherapy and postradiotherapy. Especially, we found that in comparison with those in the poor group, the percentages of two cells in the good response group were markedly increased during radiotherapy and they had a significantly positive correlation. During radiotherapy, the proportions of MDSCs were clearly increased in adenocarcinoma patients and the percentages of CD68CD163M2-like macrophages were markedly elevated in squamous carcinoma patients. We found that after radiotherapy, the expressions of eotaxin, MIP-1, MCP-1, and BLC were significantly increased in NSCLC patients. Further results showed that the low levels of eotaxin and TNF RII expression before radiotherapy could predict a good therapeutic response. IL-1ra and MIP-1 had a positive relation with MDSCs or CD68CD163M2-like macrophages in NSCLC patients during radiotherapy, and eotaxin was correlated with CD68CD163M2-like macrophages but not MDSCs in NSCLC patients after radiotherapy.
MDSCs and CD68CD163M2-like macrophages serve as therapeutic response biomarkers and are associated with the expressions of plasma inflammatory cytokines for NSCLC patients during radiotherapy.
最近的研究表明，髓系来源的抑制细胞（MDSCs）和 M2 样巨噬细胞参与肿瘤的治疗；然而，它们在放疗期间非小细胞肺癌（NSCLC）的治疗反应作用鲜为人知。我们旨在探讨循环 MDSCs 和 M2 样巨噬细胞的动态变化，研究它们之间的关系，并评估它们对 NSCLC 患者放疗的治疗反应价值。
分离外周血单个核细胞来自健康对照组和不同放疗阶段的 NSCLC 患者，通过流式细胞术检测循环 MDSCs 和 M2 样巨噬细胞。通过多重 ELISA 测量 40 种血浆炎症细胞因子。
与健康对照组相比，NSCLC 患者的 MDSCs 和 CD68CD163M2 样巨噬细胞的百分比明显升高，且在放疗中明显高于放疗前。在放疗和放疗后的 NSCLC 患者中，MDSCs 与 CD68CD163M2 样巨噬细胞呈正相关。特别是，我们发现与反应差的患者相比，反应良好的患者在放疗期间两种细胞的百分比明显增加，且呈显著正相关。在放疗过程中，腺癌患者的 MDSCs 比例明显增加，鳞癌患者的 CD68CD163M2 样巨噬细胞百分比明显升高。我们发现，放疗后，NSCLC 患者的 eotaxin、MIP-1、MCP-1 和 BLC 表达明显增加。进一步的结果表明，放疗前 eotaxin 和 TNF RII 表达水平低可预测良好的治疗反应。IL-1ra 和 MIP-1 与放疗期间 NSCLC 患者的 MDSCs 或 CD68CD163M2 样巨噬细胞呈正相关，而 eotaxin与 NSCLC 患者的 CD68CD163M2 样巨噬细胞而非 MDSCs 相关。
MDSCs 和 CD68CD163M2 样巨噬细胞作为治疗反应的生物标志物，与 NSCLC 患者放疗期间血浆炎症细胞因子的表达相关。
